Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV t… Read more
Biomarin Pharmaceutical Inc (BMRN) - Net Assets
Latest net assets as of December 2025: $6.09 Billion USD
Based on the latest financial reports, Biomarin Pharmaceutical Inc (BMRN) has net assets worth $6.09 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.59 Billion) and total liabilities ($1.51 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.09 Billion |
| % of Total Assets | 80.16% |
| Annual Growth Rate | 21.84% |
| 5-Year Change | 42.53% |
| 10-Year Change | 120.04% |
| Growth Volatility | 66.5 |
Biomarin Pharmaceutical Inc - Net Assets Trend (1998–2025)
This chart illustrates how Biomarin Pharmaceutical Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biomarin Pharmaceutical Inc (1998–2025)
The table below shows the annual net assets of Biomarin Pharmaceutical Inc from 1998 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $6.09 Billion | +7.58% |
| 2024-12-31 | $5.66 Billion | +14.27% |
| 2023-12-31 | $4.95 Billion | +7.57% |
| 2022-12-31 | $4.60 Billion | +7.78% |
| 2021-12-31 | $4.27 Billion | +4.01% |
| 2020-12-31 | $4.11 Billion | +31.50% |
| 2019-12-31 | $3.12 Billion | +5.20% |
| 2018-12-31 | $2.97 Billion | +5.67% |
| 2017-12-31 | $2.81 Billion | +1.53% |
| 2016-12-31 | $2.77 Billion | +15.22% |
| 2015-12-31 | $2.40 Billion | +57.13% |
| 2014-12-31 | $1.53 Billion | +13.93% |
| 2013-12-31 | $1.34 Billion | +32.02% |
| 2012-12-31 | $1.02 Billion | +31.40% |
| 2011-12-31 | $773.05 Million | +7.78% |
| 2010-12-31 | $717.26 Million | +122.62% |
| 2009-12-31 | $322.19 Million | +16.45% |
| 2008-12-31 | $276.68 Million | +47.38% |
| 2007-12-31 | $187.73 Million | +59.36% |
| 2006-12-31 | $117.80 Million | +252.08% |
| 2005-12-31 | $-77.46 Million | -13.95% |
| 2004-12-31 | $-67.98 Million | -157.68% |
| 2003-12-31 | $117.85 Million | +19.60% |
| 2002-12-31 | $98.54 Million | -38.24% |
| 2001-12-31 | $159.55 Million | +127.95% |
| 2000-12-31 | $69.99 Million | -28.85% |
| 1999-12-31 | $98.38 Million | +234.62% |
| 1998-12-31 | $29.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biomarin Pharmaceutical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 16930600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $154.21 Million | 2.53% |
| Common Stock | $192.00K | 0.00% |
| Other Comprehensive Income | $-23.98 Million | -0.39% |
| Other Components | $5.96 Billion | 97.86% |
| Total Equity | $6.09 Billion | 100.00% |
Biomarin Pharmaceutical Inc Competitors by Market Cap
The table below lists competitors of Biomarin Pharmaceutical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Assurant Inc
NYSE:AIZ
|
$10.74 Billion |
|
Gildan Activewear Inc.
NYSE:GIL
|
$10.76 Billion |
|
Alcoa Corp
NYSE:AA
|
$10.77 Billion |
|
Trade Desk Inc
NASDAQ:TTD
|
$10.77 Billion |
|
Antero Resources Corp
NYSE:AR
|
$10.72 Billion |
|
The J. M. Smucker Company
NYSE:SJM
|
$10.72 Billion |
|
BorgWarner Inc
NYSE:BWA
|
$10.71 Billion |
|
GF Securities Co Ltd
SHE:000776
|
$10.71 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biomarin Pharmaceutical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,657,990,000 to 6,086,999,000, a change of 429,009,000 (7.6%).
- Net income of 348,901,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 85,633,999.
- Other factors increased equity by 165,741,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $348.90 Million | +5.73% |
| Other Comprehensive Income | $-85.63 Million | -1.41% |
| Other Changes | $165.74 Million | +2.72% |
| Total Change | $- | 7.58% |
Book Value vs Market Value Analysis
This analysis compares Biomarin Pharmaceutical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.82x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 42.87x to 1.82x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $1.31 | $56.05 | x |
| 1999-12-31 | $3.29 | $56.05 | x |
| 2000-12-31 | $1.95 | $56.05 | x |
| 2001-12-31 | $3.88 | $56.05 | x |
| 2002-12-31 | $1.85 | $56.05 | x |
| 2003-12-31 | $1.90 | $56.05 | x |
| 2004-12-31 | $-1.06 | $56.05 | x |
| 2005-12-31 | $-1.13 | $56.05 | x |
| 2006-12-31 | $1.39 | $56.05 | x |
| 2007-12-31 | $1.96 | $56.05 | x |
| 2008-12-31 | $2.67 | $56.05 | x |
| 2009-12-31 | $3.21 | $56.05 | x |
| 2010-12-31 | $5.71 | $56.05 | x |
| 2011-12-31 | $6.89 | $56.05 | x |
| 2012-12-31 | $8.45 | $56.05 | x |
| 2013-12-31 | $9.73 | $56.05 | x |
| 2014-12-31 | $10.44 | $56.05 | x |
| 2015-12-31 | $15.00 | $56.05 | x |
| 2016-12-31 | $16.64 | $56.05 | x |
| 2017-12-31 | $16.10 | $56.05 | x |
| 2018-12-31 | $16.74 | $56.05 | x |
| 2019-12-31 | $17.44 | $56.05 | x |
| 2020-12-31 | $21.42 | $56.05 | x |
| 2021-12-31 | $23.36 | $56.05 | x |
| 2022-12-31 | $24.36 | $56.05 | x |
| 2023-12-31 | $25.84 | $56.05 | x |
| 2024-12-31 | $28.76 | $56.05 | x |
| 2025-12-31 | $30.84 | $56.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biomarin Pharmaceutical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.73%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.83%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 1.25x
- Recent ROE (5.73%) is above the historical average (-12.16%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -41.84% | -1025.00% | 0.04x | 1.07x | $-15.24 Million |
| 1999 | -28.54% | -529.66% | 0.05x | 1.05x | $-37.91 Million |
| 2000 | -53.38% | -384.64% | 0.13x | 1.10x | $-44.36 Million |
| 2001 | -42.37% | -577.88% | 0.07x | 1.08x | $-83.56 Million |
| 2002 | -78.61% | -556.51% | 0.13x | 1.12x | $-87.32 Million |
| 2003 | -64.32% | -626.43% | 0.05x | 2.18x | $-87.58 Million |
| 2004 | 0.00% | -1005.54% | 0.08x | 0.00x | $-180.65 Million |
| 2005 | 0.00% | -289.34% | 0.13x | 0.00x | $-66.52 Million |
| 2006 | -24.22% | -33.88% | 0.18x | 3.93x | $-40.31 Million |
| 2007 | -8.42% | -13.00% | 0.15x | 4.34x | $-34.58 Million |
| 2008 | 11.14% | 10.40% | 0.33x | 3.28x | $3.16 Million |
| 2009 | -0.15% | -0.15% | 0.35x | 2.85x | $-32.71 Million |
| 2010 | 28.70% | 54.70% | 0.30x | 1.76x | $134.09 Million |
| 2011 | -6.96% | -12.20% | 0.34x | 1.69x | $-131.14 Million |
| 2012 | -11.26% | -22.84% | 0.32x | 1.54x | $-215.92 Million |
| 2013 | -13.15% | -32.15% | 0.24x | 1.67x | $-310.46 Million |
| 2014 | -8.77% | -17.88% | 0.30x | 1.63x | $-286.76 Million |
| 2015 | -7.16% | -19.31% | 0.24x | 1.55x | $-411.88 Million |
| 2016 | -22.78% | -56.43% | 0.28x | 1.45x | $-906.84 Million |
| 2017 | -4.17% | -8.91% | 0.28x | 1.65x | $-397.91 Million |
| 2018 | -2.60% | -5.18% | 0.34x | 1.49x | $-374.00 Million |
| 2019 | -0.76% | -1.40% | 0.36x | 1.50x | $-336.09 Million |
| 2020 | 20.80% | 45.90% | 0.32x | 1.42x | $443.43 Million |
| 2021 | -1.50% | -3.47% | 0.31x | 1.41x | $-491.15 Million |
| 2022 | 3.08% | 6.75% | 0.33x | 1.38x | $-318.75 Million |
| 2023 | 3.39% | 6.93% | 0.35x | 1.38x | $-327.51 Million |
| 2024 | 7.54% | 14.96% | 0.41x | 1.24x | $-138.94 Million |
| 2025 | 5.73% | 10.83% | 0.42x | 1.25x | $-259.80 Million |
Industry Comparison
This section compares Biomarin Pharmaceutical Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biomarin Pharmaceutical Inc (BMRN) | $6.09 Billion | -41.84% | 0.25x | $10.73 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |